Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of Dipeptidyl peptidase (DPP) -IV
inhibitor Vildagliptin vs. Glibenclamide on circulating endothelial progenitor cells (EPCs)
number in type 2 diabetes patients in metformin failure. Subjects will be followed for 12
months after randomization.